Aim. Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are in a bidirectional relationship. This prospective study focused on associations between parameters common to the pathogenesis of insulin resistance, inflammation and hepatic steatosis in T2DM patients with metabolic imbalance.
Introduction
With a prevalence of 24% in 2018, non- (1, 4) From the point of view of prevention, as well as for the deeper understanding of the complex patho-physiological mechanisms involved, it makes sense to suspect NAFLD in all the patients who present with metabolic risk factors such as obesity, dyslipidemia, hypertension and insulin resistance . (5, 6) Moreover, the bidirectional relationship between NAFLD and type 2 diabetes mellitus (T2DM) is widely accepted, and we know that 
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T2DM, too, is exacerbated by the same risk factors . (7) In addition, recent research has pointed to the progression from NAFLD toward NASH in tandem with the aggravation of pre-diabetes to full blown diabetes, and this should be taken into consideration when diagnosing a diabetic patient . For instance, FLI has been (3) found a valid predictor of diabetes in prediabetics within as few as 3 years. In the same study, elevated FLI values (>60)
indicative of hepatic steatosis were concurrently strong independent predictors for the risk of developing diabetes (HR = 4.97) . (8) In light of the above, it is of both scientific and clinical interest to assess the extent to which the parameters and indices for insulin resistance, inflammation and hepatic steatosis correlate. This prospective study aims to investigate such associations and their implications in T2DM patients who are struggling to achieve glycemic control and are in a state of metabolic imbalance.
Materials and methods
The present study employs data obtained 
Results
The Table 2 below.
The preliminary results with regard to the relationship between insulin resistance and inflammation in the same patients have a l re a d y b e e n p re s e n t e d i n n a t i o n a l congresses ; statistically significant ( 1 3 ) correlations were noted between HOMA-IR and the inflammation markers IL-6 (r=0. 22 table 3 ). 
Discussion
NAFLD is recognized as a public health problem of epidemic proportions, and its prevalence among T2DM patients reaches a staggering 56.8 -70%
The two medical (14) (15) . (16) .
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The other element in the chain linking insulin resistance to cardiovascular risk is the presence of subclinical inflammation. We investigated it by assessing the serum levels of IL-6 and hsCRP, two markers of particular relevance in type 2 diabetic patients given h o w i n f l a m m a t o r y c y t o k i n e s a l t e r cardiomyocytes as another form of chronic complication These intervene further by (17) .
augmenting the effects of insulin resistance: the free fatty acids resulting from the activation of intracellular kinases lead to serine phosphorylation at the level of insulin receptors and, in this way, undermine the signalling pathway of insulin In light of (18) . these insights, the relationship between i n s u l i n r e s i s t a n c e p a r a m e t e r s a n d inflammatory markers fell within the scope of our analysis.
As discussed elsewhere, the degree to which our T2DM patients are subject to subtle inflammatory processes is of material clinical interest, given the wide-ranging damage that inflammation exerts on the body The (19) .
hsCRP values recorded suggest that no less than 75% of the patients were at high risk of experiencing adverse cardiovascular events, as hsCRP > 3 mg/l in 88 cases and the median value of hsCRP was as high as 5.40 mg/l (interquartile range 8.92) even after excluding two extreme cases > 50 mg/l. cholesterol) and increased oxidative stress (7) . Also, we analyzed the levels of hsCRP in conjunction with the patients' BMI and learned that inflammation levels differ significantly between patients who are normal weight and those who are overweight (1.6 mg/l versus 9.01 mg/l, p =0.01) or obese groups (1.6 mg/l versus 10.52 mg/l, p <0.01).
The fact that the significance threshold was The average duration of disease progression was of 7 years, which is less than recorded by others . The patient distribution based on (21, 22) their T2DM evolution (<5, 5-10, >10 years) reveals that the serum levels of the studied inflammation markers did not differ Research has shown that being at high risk of developing T2DM also multiplies the risk of NAFLD fivefold . Moreover, NAFLD is not (23) necessarily a consequence, but rather one of the factors causing the metabolic syndrome or even type 2 diabetes mellitus, worsening its progression . For instance, patients (5) suffering from both T2DM and NAFLD struggle harder to achieve satisfactory glycemic control compared to diabetic persons without NAFLD . (24) 
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The cut-off values for the hepatic steatosis markers evaluated in our study are FLI > 60, HIS > 36 and NAFLD-LFS > -0.64. The first two were reached by 91% of the patients and the latter by 100% (10) (11) (12) . weight , or how FLI values higher than 60 (25) appeared to predict the risk of developing T2DM in Korean subjects monitored over a period of 2.6 years (HR = 2.84) . Also, in (26) another study enrolling type 1 diabetic steatosis using the studied markers may be inexpensive and straightforward , but its (28) reliability has yet to be confirmed by means Also, few reported using or intending to use non-invasive staging algorithms . Such (29) issues related to clinician perceptions and practices provide an interesting avenue for further research in conjunction with understanding the pathways by which NAFLD 
